Navigation Links
Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA

Calando Pharmaceuticals Inc.

Calando Pharmaceuticals Inc. (www.calandopharma.com), a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), is using its proprietary technologies in targeted polymeric delivery systems and siRNA design to design and create new, targeted siRNA therapeutics. The company is pursuing this goal through its internal research and development and also through collaborations and partnerships with pharmaceutical and biotechnology companies.

Calando Technology

Calando's cyclodextrin-containing polymers form the foundation for its two-part siRNA delivery system. The first component is a linear, cyclodextrin-containing polycation that, when mixed with small interfering RNA (siRNA), binds to the anionic "backbone" of the siRNA. The polymer and siRNA self-assemble into nanoparticles of approximately 50-80 nm diameter that fully protect the siRNA from nuclease degradation in serum. The siRNA delivery system has been designed to allow for intravenous injection. Upon delivery to the target cell, the targeting ligand binds to membrane receptors on the cell surface and the RNA-containing nanoparticle is taken into the cell by endocytosis. There, chemistry built into the polymer functions to unpackage the siRNA from the delivery vehicle. In addition to targeting tumors, the targeting of liver cells has also been accomplished in vivo.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the fu
'"/>




Page: 1 2 3

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
3. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
4. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
5. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
6. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
7. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/2/2015)... Minn. , Sept. 2, 2015  MGC Diagnostics ... scheduled a conference call to discuss its financial results ... 31, 2015. The call will be at 4:30 p.m. ... report financial results for the third quarter of fiscal ... 2015. Participants can dial (877) 317-6789 ...
(Date:9/2/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a ... with an emphasis on the treatment of primary and ... in the upcoming 17 th Annual Rodman & ... the St. Regis Hotel in New York City.  ... Chief Executive Officer, will present a corporate overview and ...
(Date:9/2/2015)... -- Kastle Therapeutics (Kastle), a biopharmaceutical company focused on ... high unmet medical needs, announced today that it ... positions. Sean McAuliffe has ... Global Marketing Director for Baxalta. Nick Smith ... and Analytics; Nick was previously Director, Forecasting and ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2Delcath To Present At The 17th Annual Rodman & Renshaw Conference 2Delcath To Present At The 17th Annual Rodman & Renshaw Conference 3Kastle Therapeutics Announces Key Additions to Commercial Leadership 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 3
... Sweden, Sept. 18 Forest,Laboratories (NYSE: FRX ... produced a significant bronchodilatory response in 17 patients,with ... trial presented today at the,European Respiratory Society (ERS) ... ) Results of the study showed ...
... Major study of more than 2,100 patients with hip fracture shows,significant 35% reduction ... The New England Journal of Medicine show, significant 28% reduction in ... ... receive osteoporosis treatments following hip fracture despite ...
Cached Medicine Technology:Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 2Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 3Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 4Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress 5First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 2First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 3First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 4First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 5First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 6First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 7First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival 8
(Date:9/2/2015)... ... ... On September 9, 2015, over 27,000 people from all over the world ... date for the state of Utah. , “We are thrilled with the overwhelming response ... doTERRA CEO. “One of the most exciting elements of our convention is the opportunity ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Brain Aneurysm Awareness Month , which was established by the Foundation in ... awareness and education, and helping fund more research remains our top priority,” commented ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to be ... being launched, and mobile device usage as a whole is something people around the ... lives. What's more people are expecting mobile versions of their favorite software. , While ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is National Prostate ... that affects more than 233,000 men each year in the United States. , Prostate ... common non-skin cancer in America, affecting 1 in 7 men. One new case occurs ...
(Date:9/1/2015)... Los Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... the American Medical Association, individuals with type 2 diabetes that participated in a three ... of diabetes three years down the line if they elected weight loss surgery at ...
Breaking Medicine News(10 mins):Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2
... cells continue to flow to newborn in minutes after birth, ... women may want to consider asking their doctors to hold ... after the baby is born, a new study suggests. , ... the blood flow from mom to baby. While not necessarily ...
... experts say , WEDNESDAY, May 26 (HealthDay News) -- Malignant ... tens of thousands of genetic mutations which, together, contribute to ... lung tumor from a heavy smoker revealed 50,000 mutations, according ... Nature . , "People in the field have always known ...
... Complete Genomics Inc., a third-generation human genome sequencing company, ... of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ... sequence and compare a patient,s primary lung tumor and ... to compare the patient,s genome before and after it ...
... treatment of anaplastic thyroid carcinoma has dramatically increased survival in ... say physicians at Mayo Clinic. Their findings will be presented ... Clinical Oncology , to be held June 4-8 in Chicago. ... to aggressively treat metastasis even when this rare cancer seems ...
... ... first Community of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest Region. ... ... the first Community of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest ...
... ... up to $100,000 per-violation penalties , ... Alexandria, VA (Vocus) May 26, 2010 -- More than ten major ... Network (CEN) offered by the National Association of Chain Drug Stores (NACDS) and RollStream. ...
Cached Medicine News:Health News:Waiting to Clamp the Umbilical Cord May Be Better for Babies 2Health News:Waiting to Clamp the Umbilical Cord May Be Better for Babies 3Health News:Single Lung Tumor Contains 50,000 Mutations 2Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:New treatment approach to rare cancer results in prolonged survival 2Health News:Houston Northwest Medical Center Becomes First Hospital in the Southwest Region Designated a Community of Respect™ Partner 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 3
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: